PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 2.92M (Avg.)
-0.48 | -4.19
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
86.85%
EBIT growth of 86.85% while CRON.TO is zero. Bruce Berkowitz would see if small gains can be scaled further.
86.85%
Operating income growth of 86.85% while CRON.TO is zero. Bruce Berkowitz would see if this modest edge can become significant.
87.46%
Net income growth of 87.46% while CRON.TO is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
87.70%
EPS growth of 87.70% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
87.70%
Diluted EPS growth of 87.70% while CRON.TO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1323.70%
Negative OCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-1323.70%
Negative FCF growth while CRON.TO is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1020.71%
Negative 10Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-1020.71%
Negative 5Y OCF/share CAGR while CRON.TO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1020.71%
Negative 3Y OCF/share CAGR while CRON.TO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
38.34%
10Y net income/share CAGR of 38.34% while CRON.TO is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
38.34%
Net income/share CAGR of 38.34% while CRON.TO is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
38.34%
3Y net income/share CAGR of 38.34% while CRON.TO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
-57.28%
Negative equity/share CAGR over 10 years while CRON.TO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-57.28%
Negative 5Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-57.28%
Negative 3Y equity/share growth while CRON.TO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-69.26%
Firm’s AR is declining while CRON.TO shows 0.00%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-32.28%
Negative asset growth while CRON.TO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-5.59%
We have a declining book value while CRON.TO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-104.07%
We cut SG&A while CRON.TO invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.